Zeigler signed a NIL deal with Spyre Sports Group which is a sports marketing and media agency based in Tennessee. A. Zakai Zeigler has inked deals with The Dairy Alliance, The Players' Lounge ...

Investors considering a purchase of Spyre Therapeutics Inc (Symbol: SYRE) stock, but cautious about paying the going market price of $18.16/share, might benefit from considering selling puts among ...

On Tuesday, Wolfe Research began coverage on Spyre (NASDAQ:SYRE), assigning the biopharmaceutical company an Outperform rating. The firm’s analyst, Andy Chen, provided a positive outlook based on ...

Wolfe Research initiated coverage of Spyre Therapeutics (SYRE) with an Outperform rating and $27 price target The company is an early stage biotech with Phase 1 readouts in 2025, offering a ...

Spyre Therapeutics has a 52 week low of $17.24 and a 52 week high of $47.97. The business’s fifty day simple moving average is $21.65 and its 200-day simple moving average is $26.41.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Navigation apps have evolved a great deal since the earlier times. In 2025, the biggest names remain Waze and Google Maps. Both possess high-end capabilities, but serve somewhat differently towards ...

WALTHAM, Mass., March 7, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing ...

Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com .